These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 39048072)
1. Relapses in giant cell arteritis: Updated review for clinical practice. Alba MA; Kermani TA; Unizony S; Murgia G; Prieto-González S; Salvarani C; Matteson EL Autoimmun Rev; 2024 Jun; 23(6):103580. PubMed ID: 39048072 [TBL] [Abstract][Full Text] [Related]
2. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study. Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579 [TBL] [Abstract][Full Text] [Related]
3. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Kötter I; Henes JC; Wagner AD; Loock J; Gross WL Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. Hellmich B; Águeda AF; Monti S; Luqmani R Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642 [TBL] [Abstract][Full Text] [Related]
5. The role of biologics in the treatment of giant cell arteritis. González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S Expert Opin Biol Ther; 2019 Jan; 19(1):65-72. PubMed ID: 30513026 [TBL] [Abstract][Full Text] [Related]
6. Treatment of giant cell arteritis. González-Gay MÁ; Pina T; Prieto-Peña D; Calderon-Goercke M; Gualillo O; Castañeda S Biochem Pharmacol; 2019 Jul; 165():230-239. PubMed ID: 31034796 [TBL] [Abstract][Full Text] [Related]
7. [From pathogenesis of giant cell arteritis to new therapeutic targets]. Samson M; Bonnotte B Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947 [TBL] [Abstract][Full Text] [Related]
8. Current and emerging diagnosis tools and therapeutics for giant cell arteritis. González-Gay MA; Pina T; Prieto-Peña D; Calderon-Goercke M; Blanco R; Castañeda S Expert Rev Clin Immunol; 2018 Jul; 14(7):593-605. PubMed ID: 29877748 [TBL] [Abstract][Full Text] [Related]
9. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411 [TBL] [Abstract][Full Text] [Related]
11. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Alba MA; García-Martínez A; Prieto-González S; Tavera-Bahillo I; Corbera-Bellalta M; Planas-Rigol E; Espígol-Frigolé G; Butjosa M; Hernández-Rodríguez J; Cid MC Medicine (Baltimore); 2014 Jul; 93(5):194-201. PubMed ID: 25181312 [TBL] [Abstract][Full Text] [Related]